Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough

被引：8

作者：

Anastasilakis, Athanasios D. ^{[1
]}

Trovas, Georgios ^{[2
]}

Balanika, Alexia ^{[3
]}

Polyzos, Stergios A. ^{[4
]}

Makras, Polyzois ^{[5
,6
]}

Tournis, Symeon ^{[2
]}

机构：

[1] 424 Gen Mil Hosp, Dept Endocrinol, Thessaloniki, Greece

[2] Natl & Kapodistrian Univ Athens, KAT Hosp, Lab Res Musculoskeletal Syst Th Garofalidis, Med Sch, Athens, Greece

[3] Asklepe Voulas Hosp, Dept Computed Tomog, Athens, Greece

[4] Aristotle Univ Thessaloniki, Sch Med, Lab Pharmacol 1, Thessaloniki, Greece

[5] 251 Hellen Airforce & VA Hosp, Dept Endocrinol & Diabet, Athens, Greece

[6] 251 Hellen Airforce & VA Hosp, Dept Med Res, Athens, Greece

来源：

JOURNAL OF CLINICAL DENSITOMETRY | 2020年 / 24卷 / 02期

关键词：

Denosumab; Discontinuation; Fracture; Osteoporosis; Rebound;

D O I：

10.1016/j.jocd.2020.10.014

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Rebound-associated vertebral fractures (RAVFs) could occur in a minority of the patients who discontinue denosumab. In such patients, denosumab is often reinstituted to rapidly suppress bone turnover and avert the risk of additional fractures. Herein we report the cases of 2 patients who sustained RAVFs, and in whom resuming denosumab treatment did not avert the occurrence of new RAVFs a few months later, despite the suppression of bone turnover markers. It seems that denosumab reinstitution cannot completely eliminate the risk of new RAVFs and that the rebound of bone turnover may not be the sole mechanism to explain this phenomenon.

引用

页码：338 / 340

页数：3

共 10 条

[1]

Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment reinitiation [J].

Anastasilakis, Athanasios D. ;

Evangelatos, Gerasimos ;

Makras, Polyzois ;

Iliopoulos, Alexios .

BONE REPORTS, 2020, 12

[2]

Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis [J].

Anastasilakis, Athanasios D. ;

Polyzos, Stergios A. ;

Makras, Polyzois .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 179 (01) :R31-R45

[3]

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases [J].

Anastasilakis, Athanasios D. ;

Polyzos, Stergios A. ;

Makras, Polyzois ;

Aubry-Rozier, Berengere ;

Kaouri, Stella ;

Lamy, Olivier .

JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 (06) :1291-1296

[4]

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].

Bekker, PJ ;

Holloway, DL ;

Rasmussen, AS ;

Murphy, R ;

Martin, SW ;

Leese, PT ;

Holmes, GB ;

Dunstan, CR ;

DePaoli, AM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066

[5]

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension [J].

Bone, Henry G. ;

Wagman, Rachel B. ;

Brandi, Maria L. ;

Brown, Jacques P. ;

Chapurlat, Roland ;

Cummings, Steven R. ;

Czerwinski, Edward ;

Fahrleitner-Pammer, Astrid ;

Kendler, David L. ;

Lippuner, Kurt ;

Reginster, Jean-Yves ;

Roux, Christian ;

Malouf, Jorge ;

Bradley, Michelle N. ;

Daizadeh, Nadia S. ;

Wang, Andrea ;

Dakin, Paula ;

Pannacciulli, Nicola ;

Dempster, David W. ;

Papapoulos, Socrates .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07) :513-523

[6]

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension [J].

Cummings, Steven R. ;

Ferrari, Serge ;

Eastell, Richard ;

Gilchrist, Nigel ;

Jensen, Jens-Erik Beck ;

McClung, Michael ;

Roux, Christian ;

Torring, Ove ;

Valter, Ivo ;

Wang, Andrea T. ;

Brown, Jacques P. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 (02) :190-198

[7]

Delayed Denosumab Injections and Fracture Risk [J].

Ensrud, Kristine E. ;

Schousboe, John T. .

ANNALS OF INTERNAL MEDICINE, 2020, 173 (07) :582-+

[8]

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report [J].

Kashii, Masafumi ;

Ebina, Kosuke ;

Kitaguchi, Kazuma ;

Yoshikawa, Hideki .

BONE REPORTS, 2020, 13

[9]

Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis A Population-Based Cohort Study [J].

Lyu, Houchen ;

Yoshida, Kazuki ;

Zhao, Sizheng S. ;

Wei, Jie ;

Zeng, Chao ;

Tedeschi, Sara K. ;

Leder, Benjamin Z. ;

Lei, Guanghua ;

Tang, Peifu ;

Solomon, Daniel H. .

ANNALS OF INTERNAL MEDICINE, 2020, 173 (07) :516-+

[10]

Second rebound-associated vertebral fractures after denosumab discontinuation [J].

Niimi, Rui ;

Kono, Toshibumi ;

Nishihara, Atsushi ;

Hasegawa, Masahiro ;

Kono, Toshihiko ;

Sudo, Akihiro .

ARCHIVES OF OSTEOPOROSIS, 2020, 15 (01)

← 1 →